Anzeige
❌
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: A2JJ99 | ISIN: US04962H5063 | Ticker-Symbol: YAG2
Tradegate
21.01.25
17:52 Uhr
0,797 Euro
+0,001
+0,13 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ATOSSA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ATOSSA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,8000,84021.01.
0,8170,85021.01.

Aktuelle News zur ATOSSA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.01.Atossa Therapeutics, Inc.: Atossa Therapeutics Applauds U.S. Surgeon General's Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer31GlobeNewswire (USA)
28.12.24Atossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Large Decrease in Short Interest30MarketBeat
12.12.24Atossa Therapeutics, Inc.: Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium7GlobeNewswire (USA)
ATOSSA THERAPEUTICS Aktie jetzt für 0€ handeln
11.12.24Atossa berichtet über vielversprechende Therapie zur Brustkrebsprävention25Investing.com Deutsch
11.12.24Atossa reports promising breast cancer prevention therapy2Investing.com
11.12.24Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density138GlobeNewswire (Europe)1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a Poster Spotlight Session During...
► Artikel lesen
10.12.24Atossa Therapeutics, Inc.: Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium4GlobeNewswire (USA)
10.12.24ATOSSA THERAPEUTICS, INC. - 8-K, Current Report1SEC Filings
20.11.24Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium288GlobeNewswire (Europe)SEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical stage biopharmaceutical company developing innovative medicines in areas...
► Artikel lesen
19.11.24ATOSSA THERAPEUTICS, INC. - 8-K, Current Report12SEC Filings
12.11.24Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update225GlobeNewswire (Europe)Announced positive topline results from KARISMA-Endoxifen Phase 2 study which demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density (MBD), addressing a key...
► Artikel lesen
05.11.24Atossa Therapeutics, Inc.: Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development14GlobeNewswire (USA)
04.11.24Atossa Therapeutics, Inc.: Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results200GlobeNewswire (Europe)(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies SEATTLE, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics...
► Artikel lesen
04.11.24ATOSSA THERAPEUTICS, INC. - 8-K, Current Report9SEC Filings
31.10.24Atossa reports promising phase 2 trial results for breast cancer drug15Investing.com
31.10.24Atossa Therapeutics, Inc.: Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer183GlobeNewswire (Europe)(Z)-endoxifen at 10 mg once daily met the primary endpoint with 19/20 (95%) receiving > 75 % of planned treatment in I-SPY-2 Phase 2 Trial Low dose (Z)-endoxifen was well tolerated and demonstrated...
► Artikel lesen
21.10.24Atossa Therapeutics, Inc.: Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer6GlobeNewswire (USA)
14.10.24Atossa Therapeutics, Inc.: Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit10GlobeNewswire (USA)
01.10.24Atossa Therapeutics, Inc.: Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum17GlobeNewswire (USA)
10.09.24Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer254GlobeNewswire (Europe)SEATTLE, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced its support of the U.S. Food and Drug Administration (FDA) for issuing...
► Artikel lesen
Seite:  1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4